Leveraging our streamlined operations from R & D to manufacturing, we have crafted a value-add model that effectively transitions from APIs to various formulations and new drug delivery systems.
Our outstanding 7 manufacturing facilities, stringent quality standards, robust compliance practices and an enviable regulatory track record combine to make our Finished Dosage business, a true value-based solution. Be it sterile, solid dosage forms or specialist filling, we accelerate the speed-to-market for our customers while mitigating risk.
We have initiated several strategic initiatives to strengthen and fortify our FDF business across generic, branded and contract manufacturing segments.
In a short span we expanded our MRs from 40 to a 100, achieved 30 market authorizations and ANDA’s and have set-up a contract research lab to support our own filings of MA and ANDA.
Having established ourselves with finished formulations in the semi regulated markets, we set our sights on growth in the regulated generic markets such as Europe, US, Canada & Australia.